Biodesix to Report First Quarter 2026 Financial Results on May 4, 2026
Globe Newswire (Mon, 20-Apr 6:00 AM ET)
Biodesix Recognized as a Top Workplace for Third Consecutive Year
Globe Newswire (Thu, 9-Apr 1:19 PM ET)
Globe Newswire (Mon, 6-Apr 11:43 AM ET)
Globe Newswire (Fri, 20-Mar 8:06 AM ET)
Biodesix Announces Fourth Quarter and Fiscal Year 2025 Results and Highlights
Globe Newswire (Thu, 26-Feb 4:01 PM ET)
Biodesix to Participate in Upcoming Investor Conferences
Globe Newswire (Tue, 24-Feb 6:00 AM ET)
Biodesix to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
Globe Newswire (Thu, 12-Feb 6:00 AM ET)
Market Chameleon (Mon, 12-Jan 4:53 AM ET)
Biodesix Surpasses Revenue Guidance and Affirms Positive Adjusted EBITDA for Q4 2025
Market Chameleon (Mon, 12-Jan 2:05 AM ET)
Biodesix Expands Bio-Rad Partnership to Accelerate High-Sensitivity Cancer Diagnostics
Market Chameleon (Wed, 22-Oct 3:06 AM ET)
Biodesix Inc is a diagnostic solutions company with a focus on lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources: providing diagnostic testing services associated with blood-based lung and COVID tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties, as well as the development and commercialization of companion diagnostics.
Biodesix trades on the NASDAQ stock market under the symbol BDSX.
As of April 20, 2026, BDSX stock price climbed to $13.17 with 24,611 million shares trading.
BDSX has a beta of -0.40, meaning it tends to be less sensitive to market movements. BDSX has a correlation of 0.00 to the broad based SPY ETF.
BDSX has a market cap of $105.36 million. This is considered a Micro Cap stock.
Last quarter Biodesix reported $29 million in Revenue and -$.49 earnings per share. This beat revenue expectation by $3 million and exceeded earnings estimates by $.45.
In the last 3 years, BDSX traded as high as $44.20 and as low as $3.44.
The top ETF exchange traded funds that BDSX belongs to (by Net Assets): VTI, VXF.
BDSX has underperformed the market in the last year with a price return of +19.9% while the SPY ETF gained +36.0%. However, in the short term, BDSX had mixed performance relative to the market. It has outperformed in the last 3 months, returning +47.6% vs +4.9% return in SPY. But in the last 2 weeks, BDSX shares have been beat by the market, returning -14.3% compared to an SPY return of +7.6%.
BDSX support price is $12.41 and resistance is $13.87 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BDSX shares will trade within this expected range on the day.